Analysts at Roth Capital and Craig-Hallum initiate coverage of Durata Therapeutics (DRTX) with BUY ratings. Both have a price target of $20.
Nine analysts have ratings on the stock, seven bullish and two neutral.
The company's lead product is delbavancin, an IV antibacterial for adult patients with acute skin and skin structure infections caused by Gram-positive bacteria.
79 mutual funds have positions, up from 68 a year earlier.
Shares currently exchange hands at $14.